Skip to main content

Table 1 Univariate and multivariate analysis of elafin-positive cells in breast cancer patients

From: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence

A: Univariate analysis, breast cancer (n = 793)

Factors

 

Elafin Negative (n = 311)

Elafin Negative (n = 482)

P value

Age of diagnosis, year

0.02

Mean

55.5

53.5

 

Median (range)

55 (26–86)

52 (25–87)

 

Stage

  

<0.0001

I

120 (38.7)

115 (24.0)

 

IIA

128 (41.3)

241 (50.2)

 

IIB

62 (20.0)

124 (25.8)

 

Unknown

1

2

 

ER

  

<0.0001

Positive

266 (85.5)

280 (58.3)

 

Negative

45 (14.5)

200 (41.7)

 

Unknown

0

2

 

PR

  

<0.0001

Positive

218 (70.1)

236 (49.2)

 

Negative

93 (29.9)

244 (50.8)

 

Unknown

0

2

 

HER-2

  

0.013

Positive

42 (13.5)

98 (20.4)

 

Negative

269 (86.5)

383 (79.6)

 

Unknown

0

1

 

Grade

  

<0.0001

I

41 (14.2)

31 (6.8)

 

II

186 (64.6)

197 (43.5)

 

III

61 (21.2)

225 (49.7)

 

Unknown

23

29

 

Tumor subtype

  

<0.0001

Luminal A

185 (61.9)

158 (33.1)

 

Luminal B

45 (15.1)

94 (19.8)

 

Her2 positive

42 (14.0)

98 (20.7)

 

Triple negative

27 (9.0)

125 (26.4)

 

Unknown

12

7

 

Recurrence

  

<0.0001

No

250 (80.9)

298 (62.3)

 

Yes

59 (19.1)

180 (37.7)

 

Unknown

2

4

 

B: Multivariate Cox proportional hazards analysis of clinicopathologic variables’ influence on breast cancer RFS in whole cohort (n = 793)

Factor

HR

Se

P

95% CI

Stage

    

I

referent

   

IIA

1.67

0.31

0.005

1.17-2.39

IIB

2.41

0.47

<0.0001

1.65-3.52

Age

0.98

0.01

<0.0001

0.97-0.99

Elafin positive

1.94

0.3

<0.0001

1.44-2.62